Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobs

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Physiology|May 17, 2021
Methodological Variations Contributing to Heterogenous Ergogenic Responses to Ischemic PreconditioningLiam O'Brien, Ira Jacobs
Clinical Journal of Oncology Nursing|March 19, 2017
Biosimilars: Considerations for Oncology Nurses
Vida Vizgirda, Ira Jacobs
Current Opinion in Supportive and Palliative Care|August 10, 2011
Denosumab: benefits of RANK ligand inhibition in cancer patientsAllan Lipton, Ira Jacobs
Exercise and Sport Sciences Reviews|April 19, 2017
Exercise Is Medicine, But Does It Interfere With Medicine?Mackenzie McLaughlin, Ira Jacobs
Frontiers in Physiology|December 15, 2022
Potential physiological responses contributing to the ergogenic effects of acute ischemic preconditioning during exercise: A narrative reviewLiam O'Brien, Ira Jacobs
Physiological Reports|January 3, 2024
Arterial desaturation rate does not influence self-selected knee extension force but alters ventilatory response to progressive hypoxia: A pilot studySaro D Farra, Ira Jacobs
Applied Optics|March 20, 2002
Optimal dispersion precompensation by pulse chirpingIra Jacobs, John K Shaw
Medicine and Science in Sports and Exercise|June 5, 2004
Effects of acute modafinil ingestion on exercise time to exhaustionIra Jacobs, Douglas G Bell
The Lancet. Oncology|September 7, 2010
Safety of denosumab in giant-cell tumour of boneDavid Thomas, Phillipe Carriere, Ira Jacobs
Breast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira Jacobs
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Physiology|May 17, 2021
Methodological Variations Contributing to Heterogenous Ergogenic Responses to Ischemic PreconditioningLiam O'Brien, Ira Jacobs
Clinical Journal of Oncology Nursing|March 19, 2017
Biosimilars: Considerations for Oncology Nurses
Vida Vizgirda, Ira Jacobs
Current Opinion in Supportive and Palliative Care|August 10, 2011
Denosumab: benefits of RANK ligand inhibition in cancer patientsAllan Lipton, Ira Jacobs
Exercise and Sport Sciences Reviews|April 19, 2017
Exercise Is Medicine, But Does It Interfere With Medicine?Mackenzie McLaughlin, Ira Jacobs
Frontiers in Physiology|December 15, 2022
Potential physiological responses contributing to the ergogenic effects of acute ischemic preconditioning during exercise: A narrative reviewLiam O'Brien, Ira Jacobs
Physiological Reports|January 3, 2024
Arterial desaturation rate does not influence self-selected knee extension force but alters ventilatory response to progressive hypoxia: A pilot studySaro D Farra, Ira Jacobs
Applied Optics|March 20, 2002
Optimal dispersion precompensation by pulse chirpingIra Jacobs, John K Shaw
Medicine and Science in Sports and Exercise|June 5, 2004
Effects of acute modafinil ingestion on exercise time to exhaustionIra Jacobs, Douglas G Bell
The Lancet. Oncology|September 7, 2010
Safety of denosumab in giant-cell tumour of boneDavid Thomas, Phillipe Carriere, Ira Jacobs
Breast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira Jacobs
Pageof 9